Reflections and perspectives on adjuvant treatment in the setting of resected hepatocellular carcinoma

Abstract

Hepatectomy is a curative procedure in selected patients affected by hepatocellular carcinoma (HCC). However, recurrence rates are as high as 70% five years after resection, and having a valid postoperative systemic regimen would represent a significant improvement in the care of HCC patients. While burgeoning evidence is emerging around the use of immunotherapy in the setting of resected HCC, little is yet known to allow the widespread use of immunotherapy after surgery. Here, we pointed out some reflections and perspectives on adjuvant strategies for patients with resected HCC and discussed potential benefits and drawbacks.

Keywords

Hepatocellular carcinoma / surgery for hepatocellular carcinoma / HCC / adjuvant chemotherapy / immunotherapy

References

[1] Bruix J,Mazzaferro V.STORM investigatorsAdjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Oncol2015;16:1344-54

[2] Ishizuka M,Nemoto T.Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: a randomized controlled trial.Asian J Surg2016;39:149-54

[3] Xia Y,Li J.Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.Ann Surg Oncol2010;17:3137-44

[4] Reig M,Rimola J.BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.J Hepatol2022;76:681-93 PMCID:PMC8866082

[5] Famularo S,Cipriani F.ITALI.CA Group and HE.RC.O.LE.S. Group. Hepatectomy versus sorafenib in advanced nonmetastatic hepatocellular carcinoma: a real-life multicentric weighted comparison.Ann Surg2022;275:743-52

[6] Torzilli G,Kokudo N.A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West study group.Ann Surg2013;257:929-37

[7] Finn RS,Ikeda M.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905.

[8] Ren Z,Bai Y.Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.Lancet Oncol2021;22:977-90

[9] Abou-Alfa GK,Kudo M.Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.NEJM Evid2022;1:EVIDoa2100070.

[10] Kelley RK,Cheng A-L.Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol2022;23:995-1008.

[11] Llovet JM,Merle P.Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.Lancet Oncol2023;24:1399-410

[12] Qin S,Gu S.Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.Lancet2023;402:1133-46

[13] Qin S,Cheng AL.IMbrave050 investigatorsAtezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.Lancet2023;402:1835-47

[14] Manfredi GF,John C.Mechanisms of resistance to immunotherapy in hepatocellular carcinoma.J Hepatocell Carcinoma2023;10:1955-71 PMCID:PMC10629523

[15] Dudley JC,Le DT.Microsatellite instability as a biomarker for PD-1 blockade.Clin Cancer Res2016;22:813-20

[16] Gotwals P,Cipolletta D.Prospects for combining targeted and conventional cancer therapy with immunotherapy.Nat Rev Cancer2017;17:286-301

[17] Buonaguro L,Cavalluzzo B,Tagliamonte M.Immunotherapy in hepatocellular carcinoma.Ann Hepatol2019;18:291-7

[18] Keenan BP,Kelley RK.Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.J Immunother Cancer2019;7:267 PMCID:PMC6798343

[19] Polidoro MA,Cazzetta V.Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells.World J Gastroenterol2020;26:4900-18 PMCID:PMC7476172

[20] Tu JF,Ying XH.Regulatory T cells, especially ICOS⁺ FOXP3⁺ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival.Sci Rep2016;6:35056 PMCID:PMC5057140

[21] Tian T,Whitacre JM.The origins of cancer robustness and evolvability.Integr Biol2011;3:17-30

[22] Li H,Tao K.Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.Hepatology2012;56:1342-51

[23] Charoentong P,Angelova M.Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade.Cell Rep2017;18:248-62

[24] Liu C,Zhou Z.Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.Br J Cancer2018;119:80-8 PMCID:PMC6035200

[25] Sia D,Martinez-Quetglas I.Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features.Gastroenterology2017;153:812-26